Author: admin

  • Robin Wright found it ‘liberating’ to leave US to live in UK

    Robin Wright found it ‘liberating’ to leave US to live in UK

    Robin Wright is the latest Hollywood celebrity to say she’s happily living in the U.K.

    “America is a (expletive) show,” she told The Sunday Times in an interview published Aug. 30. She did not raise political issues in the conversation. “I love being in this country. There’s a freedom of self here. People are so kind. They’re living.

    “They’re not in the car in traffic, panicked on a phone call, eating a sandwich. That’s most of America. Everything’s rush, competition and speed.”

    She concluded: “It’s liberating to be done. Be done with searching, looking and getting 60% of what you wanted.”

    Wright has largely worked in England for the past several years, bouncing between rental homes. In Los Angeles, she says, “Everyone’s building a huge house and I’m just done with all that − I love the quiet.”

    What does mystify her is the British fixation on class, she told the Times. “It’s very evident when you’re in a room and you feel the judgment or the praise of someone who’s more elevated,” she says. “I’m trying to figure it out. Why are you guys so obsessed with who went to this boarding school or this university?”

    While living in the England, “I’ve met my person. Finally,” she said, referencing Henry Smith, a British-Australian architect she’s been involved with about a year. “I love being alone and I’ve done that many times. But I’m, like, I want to grow old with somebody, and travel and see the world.”

    Wright, 59, has been married three times, including to Sean Penn, with whom she has daughter Dylan and son Hopper. She said she doesn’t want to wed again. “No. God no. Why? That’s just unnecessary.”

    Her new Amazon Prime series “The Girlfriend,” a thriller about a mom (played by Wright) with a bad feeling about her son’s (Laurie Davidson) new love interest (Olivia Cooke), streams Sept. 10.


    Continue Reading

  • Evolution in progress: How ocean microbes shed genes to survive

    Evolution in progress: How ocean microbes shed genes to survive

    In some of the leanest waters on Earth, life survives by teaming up. Microscopic algae known as diatoms and nitrogen-fixing cyanobacteria strike a bargain. The bacteria pull nitrogen from the air and hand it to their hosts, while the diatoms – ace photosynthesizers – pay in sugars powered by sunlight.

    A new study led by Stockholm University shows these alliances don’t just keep the ocean’s pantry stocked. They also capture evolution in the act, offering rare, step-by-step snapshots of how symbiotic bacteria shed genes and slide into deeper dependence on their hosts.


    The researchers examined partnerships between diatoms and cyanobacteria in the genus Richelia. By comparing Richelia genomes at different host intimacy levels, the team mapped stages of increasing symbiont integration.

    From free-living to dependent

    Not all Richelia bacteria occupy the same address. Some cling to the diatom’s exterior, others tuck into the narrow space beneath the silica shell (the frustule), and the most committed residents move right in.

    That gradient of living arrangements – the “continuum of integration” – maps neatly onto a classic evolutionary pattern in symbiosis. The more a symbiont relies on its host, the more it tends to live inside, and the more of its own genome it can afford to discard.

    “In general, as symbionts become more dependent on their hosts, they become more integrated into the host, for example, live inside the host cell, and start to lose genomic information that is redundant with their hosts,” said Professor Rachel Foster, a co-author of the study.

    Having multiple, coexisting stages in a single system gives researchers something they rarely get in nature: different time points of the same evolutionary process, all available for side-by-side comparison.

    Ocean genes in transition

    Using comparative genomics, postdoctoral researcher Vesna Grujcic and colleagues parsed which genes Richelia keep and which they lose as they lean more on their diatom partners.

    A pangenome analysis identified the core set shared by all Richelia, as well as accessory genes that vary among lineages.

    The team also tracked hallmarks of genome streamlining. These included overall genome size, the fraction of DNA devoted to protein-coding regions, the length of intergenic spacers, and the prevalence of pseudogenes (broken genes that no longer function).

    “As Richelia become more dependent on their hosts, the set of genes they carry changes a lot,” said Grujcic. “We can see which genes disappear and which stay – giving us a rare view of how these partnerships evolve step by step.”

    Shrinking genomes, bigger dependence

    Comparing Richelia to other nitrogen-fixing cyanobacterial symbionts revealed both shared themes in gene loss and ocean-specific lineage quirks. This underscores that there isn’t a single recipe for becoming a symbiont – there are family styles.

    Crucially, deeper integration doesn’t just trim the parts list; it reshapes the genome’s architecture. More integrated Richelia typically have smaller genomes, a higher proportion of coding DNA, and fewer long non-coding stretches.

    Those features point to a streamlined lifestyle in which the host picks up more of the metabolic slack, allowing the symbiont to jettison pathways it no longer needs to handle alone.

    Genome clutter hides gene loss

    One puzzle stood out. In Richelia that live squeezed between the diatom’s wall and membrane – a halfway house on the road to full integration – the genome wasn’t much smaller. It was comparable to that of the least integrated, free-surface dwellers.

    In fact, despite missing many of the same metabolic pathways as the most internal symbionts, these “semi-internal” genomes hadn’t shrunk as expected.

    The culprit, it turns out, was genomic clutter. Researcher Theo Vigil-Stenman cataloged a surge of insertion sequences and transposons in these partially integrated strains. These so-called “jumping genes” can copy and paste themselves around the genome.

    That extra cargo inflates genome size even as functional content falls, masking the underlying trend toward streamlining. In other words, a genome on a diet can still look bulky if it’s stuffed with mobile DNA.

    A living window into symbiosis

    For evolutionary biologists, this system is a gift. Transitional symbioses are notoriously hard to catch; most known partnerships are either relatively loose or ancient and fully locked in.

    Diatom–Richelia alliances capture multiple rungs on the ladder at once, letting scientists connect lifestyle, location in or on the host, and the fine-scale mechanics of genome change.

    “What excites me is different steps on the way to a fully integrated symbiont exist at the same time,” said Daniel Lundin from Linnaeus University. “This allowed us to study the genetics behind how evolution towards complete dependence happened.”

    From ocean genes to future crops

    Beyond satisfying curiosity, the findings have practical resonance. Nitrogen fixation – the trick Richelia perform for their hosts – underpins marine productivity and global nutrient cycles.

    Understanding how these symbioses assemble and are maintained can sharpen models of ocean ecology, especially in nutrient-poor regions where partnerships like these sustain food webs from the bottom up.

    There’s also an applied horizon. Agriculture has long dreamed of cereals that fix nitrogen, reducing farmers’ costs and the environmental toll of fertilizers.

    Though not crops, diatoms reveal principles for stabilizing low-oxygen niches for nitrogenase, offering valuable lessons for biology. Managing gene-loss cascades in symbionts could guide synthetic biology to engineer plants with similar nitrogen-fixing services.

    Mysteries of symbiosis

    The study focuses on the symbionts; the hosts have their own evolutionary stories to tell. How has living with Richelia reshaped diatom genomes? Which host genes facilitate the different levels of bacterial integration, from attachment to full residency?

    How do environmental shifts – warming seas, stratification, nutrient changes—drive these partnerships toward or away from tighter dependence?

    Answering those questions will require more genomes, more environmental sampling, and experiments that probe how host and symbiont negotiate the terms of their living arrangement.

    But this much is clear already: in the ocean’s smallest alliances, we can see evolution’s gears turning – one lost gene, one mobile element, one deepening dependency at a time.

    The study is published in the journal Current Biology.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

    ICD treatment does not lower death risk in patients with abnormal ECG after myocardial infarction

    Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and abnormal ECG markers, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

    An implantable cardioverter defibrillator (ICD) is a small electrical device fitted in the chest that detects irregular and fast heart rhythms. ICD therapy is used in patients with a prior cardiac arrest or severely impaired left ventricle (LV) pumping ability (severe LV systolic dysfunction).

    Principal Investigator, Professor Derek Exner from the Libin Cardiovascular Institute, Calgary, Canada, explained why the REFINE-ICD trial was conducted: “From earlier studies we knew that the risk of death was high after a myocardial infarction (MI), notably among patients with persistent, moderate LV systolic dysfunction and ECG markers associated with ventricular arrhythmia risk. We tested the hypothesis that an ICD may help these patients live longer than those who receive optimal medical therapy alone.”

    The open-label, investigator-initiated REFINE-ICD trial was conducted in Canada, USA, Europe, Middle East and Africa. In total, nearly 2,000 patients with a prior MI (≥2 months) underwent ambulatory ECG testing to assess two markers of ventricular arrhythmia risk: heart rate turbulence and T wave alternans. Of these, 597 patients with LVEF 36−50%, impaired heart rate turbulence and abnormal T wave alternans were randomized to an ICD added to medical therapy or medical therapy alone.

    The mean age of the patients was 65 years and 19% were women. Overall mortality was higher in patients with both abnormal ECG markers compared with those without (hazard ratio [HR] 2.59; 95% confidence interval [CI] 1.97 to 3.40; p<0.001).

    During mean follow-up of around 5.7 years in randomized patients with abnormal ECG markers, total mortality was not reduced with ICDs: 24.5% of patients died in the ICD group and 21.3% died in the control group (HR 1.07; 95% CI 0.77 to 1.50; p=0.69). Almost half of deaths (47.4%) were adjudicated as non-cardiac deaths. Cardiac mortality was not reduced in the ICD group vs. controls (8.8% vs. 7.6%, respectively; HR 1.11; 95% CI 0.63 to 1.945). Sudden cardiac death occurred in 2.6% of patients in the ICD group and 3.8% in the control group (HR 0.66; 95% CI 0.27 to 1.62).

    Summing up, Professor Exner said: “In this trial, patients with a prior MI, persistent moderate LV systolic dysfunction and ECG markers of ventricular arrhythmia risk had twice the incidence of death as similar patients without these risk markers. Although overall, the risk of death was lower than expected and half of all deaths were non-cardiac. Importantly, ICD therapy did not reduce total mortality, cardiac death and sudden cardiac death. Further research efforts are needed to better manage these patients.”

    Source:

    European Society of Cardiology (ESC)

    Continue Reading

  • Param Sundari box office collection day 4: Sidharth Malhotra, Janhvi Kapoor film sees sharp dip, earns less than ₹5 cr | Bollywood

    Param Sundari box office collection day 4: Sidharth Malhotra, Janhvi Kapoor film sees sharp dip, earns less than ₹5 cr | Bollywood

    Updated on: Sept 01, 2025 10:15 pm IST

    Param Sundari box office collection day 4: Directed by Tushar Jalot, the romantic comedy opened to mixed reviews upon release.

    Param Sundari box office collection day 4: Tushar Jalota’s romantic comedy Param Sundari, starring Sidharth Malhotra and Janhvi Kapoor in lead roles, released in theatres last Friday. The film arrived with the hope of reviving the genre of Bollywood’s massy rom-com, but its collections have not shown much strength on that note. Now, as per the latest update on Sacnilk, Param Sundari has seen a huge dip on the first Monday. (Also read: ‘Effortless, charming, pure magic’: Kiara Advani gushes over Sidharth Malhotra in her glowing review of Param Sundari)

    Param Sundari box office collection day 4: Sidharth Malhotra and Janhvi Kapoor headline this romantic comedy.

    Param Sundari drops the coconut on Monday

    As per Sacnilk, Param Sundari collected 3.50 crore on Monday, as per early estimates. The film’s overall collection after 4 days now stands at 28.19 crore. Param Sundari opened on Friday with 7.25 crore, and went on to show growth over the weekend, registering the highest on Sunday with 30.25 crore.

    Param Sundari had an overall 10.42% Hindi Occupancy on Monday.

    Param Sundari is no match for Saiyaara, the Mohit Suri-directed film that became a box office sensation last month. Headlined by newcomers Ahaan Panday and Aneet Padda, the film earned 22.50 crore on its first Monday and had already crossed the 100 crore mark by then. Param Sundari is nowhere near that mark.

    About Param Sundari

    Param Sundari revolves around the cross-cultural romance between the two leads, one from Delhi and the other from Kerala. Apart from Sidharth Malhotra and Janhvi, the film also stars Rajeev Khandelwal and Aakash Dahiya in pivotal roles. “Sundari is deeply personal to me. Her grace, quiet strength, and love for her roots resonate with my own South Indian heritage. Shooting in Kerala, surrounded by such beauty, I felt an emotional connection to her world that I hope the audience will feel too,” said Janhvi in a statement about her character.

    Upon release, the film was criticised for its stereotypical projection of Malayalis, lack of chemistry between the leads and a lacklustre plot.


    Continue Reading

  • Recent Windows 11 update isn’t behind gaming SSD failures, says Microsoft

    Recent Windows 11 update isn’t behind gaming SSD failures, says Microsoft

    Microsoft has responded to reports that a recent Windows 11 security update has caused gaming SSDs to fail. According to the company, a “thorough investigation” left the company in no doubt that its recent KB5063878 security update isn’t the cause behind these mysterious drive failures.

    Despite those earlier Windows 11 SSD failure reports, Microsoft hasn’t been able to replicate the issue on its own Windows 11 PCs. That leaves plenty of unanswered questions, especially with regards to identifying the cause behind the issue. While plenty of drives have so far not been listed as affected, such as Samsung 990 Pro and WD Black SN7100 that you can find on our best gaming SSD guide, there’s still cause for concern until the reason for the problem is resolved.

    Microsoft issued this news via a statement made in a service update, and since reported by Tom’s Hardware. The statement confirmed that the company found “no connection” between the KB5063878 update in August and the “types of hard drive failures reported on social media.” Despite working with hardware manufacturers, it hasn’t been able to replicate the issue itself, either.

    This error causes some gaming SSDs to disappear from Windows during periods of heavy data writes. Restarting your PC does, in most cases, cause the drive to reappear, although not in every instance, and with data loss almost guaranteed to occur due to the drive’s sudden disappearance.

    As we reported at the time, initial data suggested that gaming SSDs with Phison data controllers were seemingly the most affected. Phison was unable to replicate the issue either, however, while other reports suggested that SSDs using rival chips were also seemingly affected.

    As of now, there’s no clear answer as to what might be causing this issue. If you’re running Windows 11, keep an eye on your SSD health, especially when you’re writing a lot of data to it, such as when you’re installing a new game. If you’re worried, make sure to keep your important data backed up using cloud storage or by using an external hard drive to avoid data loss that you can’t recover from.

    You can check out our choice of the best external gaming SSD if you want to grab a fast and portable drive to keep your data on hand.

    Having trouble with your gaming PC? If you’ve been affected by this issue and you believe you know why, feel free to start a conversation in our Discord server with staff and other readers.

    Continue Reading

  • Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

    Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

    Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery (MINS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

    MINS is a common and serious complication, which has been found to account for approximately 13% of all deaths within 30 days of surgery. Explaining the rationale of the PREVENT-MINS trial, Principal Investigator, Professor Wojciech Szczeklik from Jagiellonian University Medical College, Krakow, Poland, said: “It has been proposed that increased heart rate at the time of surgery leads to higher myocardial oxygen consumption, a supply-demand mismatch and myocardial injury. Giving beta-blockers around the time of surgery lowers heart rate and decreases the risk of myocardial infarction, but these benefits may be offset by increased risk of hypotension, death and stroke. Ivabradine is a currently available medicine used in angina and heart failure that more selectively slows heart rate than beta-blockers. The PREVENT-MINS trial assessed whether ivabradine could prevent MINS in patients after noncardiac surgery with, or at risk of, atherosclerotic disease.”

    The double-blind, placebo-controlled, randomized PREVENT-MINS trial was conducted at 26 hospitals in Poland. Eligible patients were aged ≥45 years and had either established atherosclerotic disease (i.e. coronary artery disease, peripheral artery disease or prior stroke) or substantial risk factors for atherosclerotic disease (e.g. diabetes, hypertension and age ≥70 years). Patients were randomised 1:1 to receive ivabradine (5 mg orally twice daily for up to 7 days, starting one hour before surgery) or placebo. The primary outcome was MINS within 30 days from randomization. The trial had intended to enrol around 2,500 patients; however, the independent Data Monitoring Committee recommended early termination in March 2025 for futility, based on the prespecified interim analysis.

    All 2,101 participants who underwent randomization were included in the intention-to-treat population. The median age was 70.0 years and 49.4% were women.

    MINS occurred in 17.0% of patients in the ivabradine group and 15.1% in the placebo group (relative risk [RR] 1.12; 95% confidence interval [CI] 0.92 to 1.37; p=0.25). In prespecified subgroup analyses, ivabradine was associated with an increased risk of MINS among patients with a history of coronary artery disease (RR 1.49; 95% CI 1.03 to 2.16) but not among patients without a history of coronary artery disease (RR 0.98; 95% CI 0.78 to 1.24).

    The intraoperative mean heart rate was lower in the ivabradine group by 3.2 beats per minute than in the placebo group, with no difference in intraoperative mean arterial pressure. Clinically important bradycardia was more common in the ivabradine group (RR 1.18; 95% CI 1.00 to 1.40).

    Ivabradine did not reduce the risk of MINS in patients undergoing noncardiac surgery. Heart-rate lowering was modest and the possible higher MINS incidence in patients with known coronary artery disease is contrary to our original hypothesis. Further research is needed to establish a method to safely control the heart’s stress associated with noncardiac surgery.”


    Professor Wojciech Szczeklik, Jagiellonian University Medical College, Krakow, Poland

    Source:

    European Society of Cardiology (ESC)

    Continue Reading

  • Indian football team loses to Iran 3-0 after late slip-up

    Indian football team loses to Iran 3-0 after late slip-up

    The Indian men’s football team went down 3-0 to the Islamic Republic of Iran in their second Group B match of the CAFA Nations Cup 2025 at the Hisor Central Stadium in Dushanbe, Tajikistan, on Monday.

    After a goalless first half, Amirhossein Hosseinzadeh (60’) put Iran in the lead, before substitutes Ali Alipour (89’) and Mehdi Taremi (90+6’) added two late goals to hand the three-time Asian champions the three points.

    The win placed Iran on top of Group B with two wins from as many matches. The Indian football team is second with one win and a loss. Afghanistan and Tajikistan will play their second match of Group B later in the day.

    Defending champions Iran, 20th in the FIFA Rankings, pegged the world No. 133 India back from the start, drawing some early saves from India goalkeeper Gurpreet Singh Sandhu.

    The Indian defence stabilised their operations at the back after the opening exchanges, managing to keep Iran from producing any clear-cut chances.

    Efforts from Mohammad Amin Hazbavi and Omid Noorafkan, a little after the quarter-hour mark, went wide, while Gurpreet managed to block a dangerous cut-back from Mahdi Hashemnezhad.

    India had their first chance in the 24th minute, when Suresh Singh Wangjam’s cross was trapped inside the Iran box by Irfan Yadwad, who laid it off for Nikhil Prabhu. The midfielder’s shot, however, was blocked.

    India began to gain more confidence as the clock ticked past the half-hour mark, and they managed to produce a passage of play in Iran’s third.

    The Blue Tigers managed to produce a couple of switch plays to the right wing to Vikram Partap Singh, who could run at Mohammad Naderi, but Iran negotiated the danger on both occasions.

    Minutes later, Gurpreet was again called into action as he got down low to save a snapshot from Noorafkan.

    India defended in a coordinated manner in the first half, managing to frustrate Iran.

    The second half began much in the same fashion – India allowing Iran to keep possession of the ball, while staving them off near the defensive third.

    It took Iran an hour to open the scoring. Hossein Kanaani hung up a cross at the far post towards Hosseinzadeh, whose header was blocked by India defender Rahul Bheke.

    The ball, however, dropped kindly for Hosseinzadeh, who finished it from close range.

    India head coach Khalid Jamil, looking for avenues to get back in the game, brought on Manvir Singh Jr., Mahesh Naorem, and Jithin MS. The attacking changes gave the Blue Tigers some impetus going forward, and Manvir’s cross found Bheke at the near post in the 72nd minute, but the defender’s header went wide.

    Continue Reading

  • India allows production of ethanol from sugarcane juice, molasses – Reuters

    1. India allows production of ethanol from sugarcane juice, molasses  Reuters
    2. Ethanol Production: No Restrictions in 2025-26  Rediff
    3. Indian govt gives sugar mills freedom to decide on ethanol production  BusinessLine
    4. Ethanol Production Unrestricted: Boosting India’s Biofuel Program  Devdiscourse
    5. Govt allows production of ethanol from sugarcane juice syrup, molasses  The Economic Times

    Continue Reading

  • How Riz Ahmed Reimagined ‘Hamlet’ as a Contemporary Thriller

    How Riz Ahmed Reimagined ‘Hamlet’ as a Contemporary Thriller

    Riz Ahmed thinks Shakespearean scholars don’t get what makes Hamlet tick. The Danish prince, he
    says, isn’t on the verge of suicide in his “To be or not to be” soliloquy — he’s trying to man up.

    “It’s not ‘Should I end it all?’” says Ahmed, who speaks the iconic lines in a new “Hamlet” that debuted at the Telluride Film Festival and will screen at the Toronto Film Festival. “It’s about ‘Are we willing to live under injustice? Do you fight or do you give up?’”

    Nor does Ahmed accept the usual portrayal of Hamlet as a man plagued by indecision. On-screen,
    his Hamlet is a coiled ball of outrage waiting for the right moment to avenge his father. “He’s continuously active,” Ahmed says. “He’s investigating, strategizing, gathering evidence while he psyches himself up to do the unthinkable.”

    This adaptation of “Hamlet” breaks with tradition in other ways, moving its setting to contemporary
    London and exchanging a royal court for McMansions populated by a group of South Asian moguls, their families and their underlings. It also pares down the text, excising characters (farewell, Horatio!) and scenes so the focus is firmly on its tortured protagonist.

    “We did away with anything that didn’t heighten the subjectivity of the experience,” Ahmed says. “We kept all the parts that brought us into Hamlet’s mind and give viewers a sense of what he’s feeling.”

    But its blistering look at power and corruption remains intact, and is even more relevant as the world tilts towards kleptocracy.

    “There used to be unspoken rules,” says director Aneil Karia. “But now people aren’t even trying
    to hide their criminality. The ground is shifting under Hamlet’s feet. And like so many people these days, he’s revolted at what’s happening but feels powerless to change it.”

    Ahmed first fell in love with “Hamlet” as a teenager when his English teacher, Mr. Roseblad, suggested he read the play.

    “It was a time when I felt like I really didn’t belong,” Ahmed says. “And like so many people over such a long time, I found myself in that play. I saw a character who also felt that he didn’t fit in.”

    Even after Ahmed grew up and found success, starring in blockbusters like “Rogue One: A Star Wars Story” and earning an Oscar nomination for “Sound of Metal,” he kept dreaming about putting his imprint on the moody prince. He labored for nearly a decade on the script, searching for the perfect creative partner. Ultimately, he found it in Karia, who directed Ahmed in the Oscar-winning short film, “The Long Goodbye.” That film was based on Ahmed’s hip-hop album of the same name, and he felt that Karia had a unique ability to translate poetry into action.

    “We want to democratize Shakespeare and not make it something stuffy and distant,” Ahmed says. “And Aneil understood how to make it feel lived in and urgent and contemporary, and have that action thriller feel to it.”

    Yes, you read that right. Shakespeare’s sprawling, four-hour opus has been slimmed down into something half that length and far more kinetic. That includes the “To be or not to be” speech, which is delivered by Hamlet as he drives a car at breakneck speed, swerving through traffic.

    “The question was always, ‘how can this speech feel alive and visceral?’” says Karia. “And the answer was to have him behind the wheel of a speeding car heading towards a lorry.”

    Continue Reading

  • Revolut valuation jumps to $75bn with staff set for payout opportunity | Revolut

    Revolut valuation jumps to $75bn with staff set for payout opportunity | Revolut

    Revolut employees are in line for a payout bonanza after the UK fintech firm launched a share sale that has pushed its valuation up by two-thirds to $75bn (£55bn).

    The secondary sale, which prices each share at $1,381.06, will secure the finance app’s position as one of the world’s most valuable fintech firms, having last been valued at $45bn last year.

    Employees will be allowed to sell up to 20% of their personal holdings to new and existing investors over the coming weeks, with payouts likely to follow in the early autumn.

    The secondary share sale, which was announced to staff on Monday, comes after Revolut boosted its annual profits by more than 150% in 2024 to £1bn, following a jump in subscriptions and revenues from its wealth and crypto trading divisions.

    Revolut’s founder and chief executive, Nik Storonsky, has already enjoyed a $200m-$300m windfall as a result of a separate share sale that valued the company at $45bn last summer, according to reports. Storonsky is said to be in line for multibillion-dollar fortune if he manages to push the fintech company’s valuation past $150bn (£110bn).

    A Revolut spokesperson said on Monday: “As part of our commitment to our employees, we regularly provide opportunities for them to gain liquidity. An employee secondary share sale is currently in process, and we won’t be commenting further until it is complete.”

    The announcement will be a boon for longstanding staff, but the timing has sparked speculation that Revolut’s much-anticipated stock market debut may be further delayed.

    “This could be a sign that the company will either IPO soon or that its employees are getting antsy about the lack of an IPO and want to release their equity in the firm rather than wait for the IPO,” said Kathleen Brooks, research director at online broker XTB.

    “Whatever this moves signals, it is deep shame that Revolut is not planning to IPO in the UK,” she added.

    Storonsky suggested last December that New York could be a better fit for the company’s IPO because of the regulatory environment and the size of the market. A US listing would be a major blow to the City and the London Stock Exchange, which has suffered from a growing number of defections.

    Revolut bosses have grown frustrated with UK regulators, who have been slow to grant the fintech a full banking license that would allow it to hold customer deposits and branch out into more lucrative products such as loans and mortgages.

    skip past newsletter promotion

    The challenge, in part, was convincing regulators that Revolut had addressed accounting issues and EU regulatory breaches, as well as reputational concerns, including an aggressive corporate culture. The fintech company says it has since resolved those accounting and regulatory problems, and has made efforts to improve its working culture.

    The fintech waited three years for initial approval, which was finally granted in July 2024, and has remained on a restricted UK banking licence since.

    The chancellor, Rachel Reeves, tried to secure a meeting with watchdogs and regulators earlier this year amid the delay, but was blocked by Bank of England governor, Andrew Bailey, amid concerns that the chancellor was meddling in a process that should be independent from government internventions and influence. .

    Continue Reading